Arcus Biosciences (RCUS) Payables (2017 - 2026)

Arcus Biosciences' Payables history runs 10 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• In Q1 2026, Payables rose 77.27% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (up 77.27% YoY), while the FY2025 annual figure was $42.0 million, up 133.33% from the prior year.
• Payables was $39.0 million for Q1 2026 at Arcus Biosciences, down from $42.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $42.0 million in Q3 2025 to a low of $10.5 million in Q3 2022.
• Historically, Payables has averaged $22.4 million across 5 years, with a median of $18.1 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Payables plunged 45.41% in 2023, then soared 223.08% in 2025.
• A 5-year view of Payables shows it stood at $20.0 million in 2022, then retreated by 15.0% to $17.0 million in 2023, then climbed by 5.88% to $18.0 million in 2024, then jumped by 133.33% to $42.0 million in 2025, then decreased by 7.14% to $39.0 million in 2026.
• The last three Payables figures came in at $39.0 million (Q1 2026), $42.0 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.